No-one even knows if it is possible to make a vaccine against COVID-19 and already there is an escalating row about cost and equitable access if one succeeds in clinical trials.
This week saw some mixed news in coronavirus research as questions were raised about access to COVID-19 drugs as studies – and approvals – continued apace.
How do you keep a child with a suppressed immune system safe during COVID-19 lockdown? And how do you explain the dangers while protecting their – and your own – mental health?
Sanofi’s CEO Paul Hudson has courted controversy by saying the French pharma’s potential COVID-19 vaccine will likely be delivered to the US government first should it succeed in clinical t
The third webinar* in the COVID-19 monthly briefing series was designed to provide insight from life sciences thought-leaders and to generate discussion on issues that pharma and biotech co
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.